Antimicrobial Stewardship (AMS) Programs to Address Health Inequities in Resource Limited Settings

Funding Agency:
Pfizer Inc.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.One such strategic priority is decreasing the disproportionate burden of poor health outcomes faced by patients who receive healthcare in resource limited settings, specifically to address health inequities relating to treatment of infectious diseases.

Global Bridges Healthcare Alliance, based at Mayo Clinic, is dedicated to supporting global communities of practice to advance evidence-based patient care. Since 2014, Global Bridges has worked collaboratively with Pfizer GMG to support medical education and quality improvement programs in multiple clinical areas, including tobacco dependence treatment, oncology, amyloidosis, and anti-microbial stewardship.

The purpose of this RFP is to solicit programs that have identified a disparity that impacts antimicrobial stewardship in a resource-limited setting and proposes an intervention to address the disparity to improve and measure patient outcomes.

Inappropriate use of antimicrobial medicines results in adverse events (including death), increased microbiological resistance, and wasted resources.

Patients in resource-limited settings are more likely to be prescribed inappropriate antibiotics to treat their infections. Studies found that inappropriate use of antibiotics was associated with the following: culture, gender, educational status, marital status, age, number of children, health insurance and poor health care services.

Antimicrobial resistant infections disproportionately affect underserved populations.

Patients receiving care in low resource facilities do not have equitable access to effective and holistic antimicrobial stewardship (AMS) programs. As a result, these patients often receive suboptimal care reflective of racial and socioeconomic inequalities negatively impacting their outcomes and the cost of care. The inequitable access to AMS programs increases the inappropriate use of antiinfectives, hinders access to novel anti-infectives, and consequently disproportionately impacts the burden of AMR.

Proposal due date: August 26, 2021

Agency Website

Eligibility Requirements

Geographic Scope Global

• Only organizations are eligible to receive grants, not individuals or medical practice groups. • Institution must be part of a network of hospitals or institutionsto ensure dissemination of learnings/best practice and to achieve broadestimpact. • The Project Lead must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Microbiology or Epidemiology



Amount Description

Individual projects requesting up to $50,000-$100,000USD will be considered. The estimated total available budget related to this RFP is $1,000,000USD.

Funding Type





International Opportunities
Medical - Clinical Science

External Deadline

August 26, 2021